JN Nova Pharma Inc.
For important risk and disclaimer information, Click here.
For additional information, please contact:
 |
Gary Levy | Managing Director |
 |
glevy@castleplacement.com |
 |
(516) 457-0104 |
Specific Risks
- First-in-human execution risk — JN2019M5.2 has not yet entered human trials, and the deck’s 6→9→9→24-month timeline assumes no delays through Phase IA/B, Phase II, and later-stage clinical development
- Unvalidated mechanism in humans — the ACE2-replacement rationale rests on preclinical and correlational data, not demonstrated clinical efficacy
- Speculative, back-loaded deal economics — the $50M upfront and $250–500M milestone figures are “anticipated” and “potential,” contingent on securing an unconfirmed pharma partner in Q4 2027
- Small-company regulatory and capital risk — fast-track eligibility doesn’t guarantee approval, and further capital raises will likely be needed before any partnership revenue arrives, risking dilution or delay
- If unable to raise funds needed, program will stall
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment
0 Comments
